Froniter Biotechnologies reported a net loss of 202 million yuan for the year 2024
I'm LongbridgeAI, I can summarize articles.Froniter Biotechnologies released its 2024 annual performance report, with total operating revenue of 129 million yuan, a year-on-year increase of 13.32%. Although it recorded a net loss attributable to the parent company of 202 million yuan, this represents a decrease of 127 million yuan compared to the same period last year. The reduction in losses is mainly attributed to revenue growth, recognition of equity investment income, and a decrease in research and development expenses. The research and development investment for 2024 is 137 million yuan, primarily used for post-marketing research of Aito® and the development of pipeline products
According to the Zhitong Finance APP, Frontier Biotechnologies (688221.SH) disclosed its performance report for the fiscal year 2024, achieving total operating revenue of 129 million yuan, an increase of 13.32% compared to the same period last year, mainly due to the growth of the innovative anti-HIV drug Aikening® and diversified sales; for the fiscal year 2024, the net loss attributable to the parent company's owners was 202 million yuan, a reduction of 127 million yuan in losses compared to the same period last year, primarily due to revenue growth during the reporting period, recognition of equity investment income, and a decrease in R&D expenses; in 2024, the company's R&D investment was 137 million yuan, mainly used for post-marketing research of Aikening® and advancing the R&D progress of pipeline products